Our Genes Project: Advancing Precision Medicine Through Brazilian Genomic Data

Brazil is tackling genetic inequality through initiatives like the “Our Genes” project and Genoma SUS. By sequencing thousands of diverse genomes, the country aims to replace European-centric data with local records, reducing misdiagnosis rates for rare diseases and improving risk predictions for conditions like diabetes and heart disease.

For decades, the world’s medical “gold standard” for genetics has been skewed. Most of the data used to predict whether you’ll develop a heart condition or how you’ll react to a drug comes from people of European descent. In Brazil, a country defined by intense genetic mixing, this isn’t just a scientific gap—it’s a healthcare risk.

Michel Satya Naslavsky, a researcher at the Human Genome and Stem Cell Research Center (HUG-CELL), points out a stark reality: the UK Biobank, one of the world’s largest health databases, is 90% European. For Brazilians, using these “borrowed” models can lead to inaccurate risk assessments. It’s like trying to use a map of London to navigate the streets of São Paulo.

Why is European genetic data failing Brazilian patients?

Precision medicine relies on polygenic risk scores. These scores aggregate thousands of tiny DNA variations to predict your susceptibility to common killers like high blood pressure or diabetes. The problem? These variations differ wildly based on ancestry.

When clinicians apply European models to a mixed-race population, they often overestimate or underestimate a patient’s actual risk. This leads to “diagnostic blindness.” According to HUG-CELL, the only way to fix this is to build a national database that reflects the actual biological makeup of the Brazilian people.

This is where the Brazilian Online Mutation Archive (ABraOM) comes in. Launched in 2017, it uses data from healthy older adults to filter out harmless mutations. If a mutation appears in ABraOM, doctors know it’s likely a benign trait, not a disease. It’s a critical filter that prevents misdiagnosis in the SUS (Brazil’s national health network).

How will “Our Genes” and Genoma SUS change prenatal care?

The “Our Genes” project focuses on the start of life. It targets couples who may be carriers of recessive genetic disorders—where a child inherits two altered copies of a gene, one from each parent. One specific focus is Fragile X syndrome, a leading cause of intellectual disability.

Couples can voluntarily sign up for screening. If both partners carry pathogenic variants in the same gene, they face a 25% risk of having an affected child. Naslavsky emphasizes that this isn’t about “fixing” genes, but about providing genetic counseling so families can make informed decisions.

On a larger scale, the Genoma SUS project is scaling this mapping. After sequencing 21,000 complete genomes, the Ministry of Health aims to sequence another 50,000 over the next two years. With FAPESP funding 15,000 of these in São Paulo, the goal is to integrate genomic technology directly into public health workflows.

What happens when a country achieves “data sovereignty” in health?

Data sovereignty means Brazil no longer has to rely on foreign research to treat its own citizens. When a government owns its genomic data, the benefits flow back into the public system rather than into private foreign patents.

Naslavsky argues that the SUS, as the largest universal health system in the world, is the primary beneficiary of this investment. By owning the data, Brazil can develop “risk calculators” tailored specifically to its population. This means a person in Bahia or Espírito Santo gets a risk score based on people who share their genetic heritage, not someone from a village in England.

This shift moves healthcare from a “one size fits all” approach to a truly personalized model. It ensures that precision medicine isn’t a luxury for the wealthy, but a standard part of public health.

Can mixed-race populations unlock new medical discoveries?

Brazil’s genetic diversity isn’t just a challenge to be solved—it’s a goldmine for global science. Because the population is so mixed, researchers may find alternative biological pathways that don’t exist in more homogenous populations.

Naslavsky points to potential breakthroughs in Alzheimer’s disease and lipid metabolism. By studying how different ancestral fragments interact in one person, scientists might discover new therapeutic targets. These discoveries wouldn’t just help Brazilians; they could redefine how the entire world treats neurodegenerative diseases.

Essentially, the “Brazilian mix” could provide the missing piece of the puzzle for diseases that have remained stubborn in European-centric studies. You can read more about how genomic diversity impacts drug development in our previous analysis.

Frequently Asked Questions